Niacin-induced flushing: Mechanism, pathophysiology, and future perspectives.
Level 5 - mechanism / opinion, no new human data
Narrative review describing pharmacological and physiological mechanisms without systematic search or original trial data.
PubMed 39322100 · doi:10.1016/j.abb.2024.110163
What was done
This narrative review summarizes the pathophysiology and molecular mechanisms of niacin-induced cutaneous flushing, examines its clinical impact on cardiovascular therapy adherence, and reviews potential mitigation approaches, including novel dosage forms and nanomedicine.
What was found
The abstract reports no quantitative data or statistical comparisons. It outlines two primary mechanisms for niacin-induced flushing: activation of the hydroxycarboxylic acid receptor 2 (HCA2/GPR109A) that initiates prostaglandin D2 (PGD2) release leading to cutaneous vasodilation, and direct interaction with the transient receptor potential vanilloid 1 (TRPV1) channel as a distinct non-prostaglandin pathway.
Why it matters
Identifying the dual HCA2/prostaglandin and TRPV1 pathways clarifies why simple prostaglandin inhibition does not fully abolish flushing, informing formulation strategies to improve patient compliance with niacin therapy.
Limits
The abstract describes a broad narrative synthesis rather than a systematic review or meta-analysis. No sample sizes, effect sizes, risk-of-bias assessments, or original empirical data are provided.
Cited by
- supports High doses of nicotinic acid cause cutaneous flushing and hot-flash-like symptoms.